Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, the active ingredient in Lilly's obesity drug Zepbound and diabetes drug Mounjaro,

Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with plans Tuesday to file two lawsuits and send about fifty cease-and-desist letters.

Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%.

Tobacco giant Altria (NYSE: MO) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%. But it comes with risks, as its business has been struggling to grow in recent years, and its rate of dividend increases has been modest.

The stock's fall snapped a two-day winning streak.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer. Investors should weigh the potential risks and rewards of buying the stock now.